Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2016-11-07. The firm is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The firm's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. The company is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.